Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors (ARNI) (sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor (ACE-I) in heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal medical therapy. The effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Emil Eik, Feinberg, Joshua Buron, Bu, Fan-Long, Hecht Olsen, Michael, Raymond, Ilan, Steensgaard-Hansen, Frank, Jakobsen, Janus Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Heart Failure and Cardiomyopathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705560/
https://www.ncbi.nlm.nih.gov/pubmed/33257469
http://dx.doi.org/10.1136/openhrt-2020-001294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705560/
https://www.ncbi.nlm.nih.gov/pubmed/33257469
http://dx.doi.org/10.1136/openhrt-2020-001294

Ejemplares similares